Mohammad Hossein Pourhanifeh

Dr. Mohammad Hossein Pourhanifeh


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2019 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
EMElaheh Mianehsaz
Elaheh Mianehsaz
HMHamed Mirzaei
Hamed Mirzaei
MMMaryam Mahjoubin-Tehran
Maryam Mahjoubin-Tehran
ARAlireza Rezaee
Alireza Rezaee
RSRoxana Sahebnasagh
Roxana Sahebnasagh
Michael R. HamblinMichael R. Hamblin
Michael R. Hamblin
Degenerative disorders of joints, especially osteoarthritis (OA), result in persistent pain and disability and high costs to society. Nevertheless, the molecular mechanisms of OA have not yet been fully explained. OA is characterized by destruction of cartilage and loss of extracellular matrix (ECM). It is generally agreed that there is an association between pro-inflammatory cytokines and the development of OA. There is increased expression of matrix metalloproteinase (MMP) and “a disintegrin and metalloproteinase with thrombospondin motifs” (ADAMTS). Mesenchymal stem cells (MSCs) have been explored as a new treatment for OA during the last decade. It has been suggested that paracrine secretion of trophic factors, in which exosomes have a crucial role, contributes to the mechanism of MSC-based treatment of OA. The paracrine secretion of exosomes may play a role in the repair of joint tissue as well as MSC-based treatments for other disorders. Exosomes isolated from various stem cells may contribute to tissue regeneration in the heart, limbs, skin, and other tissues. Recent studies have indicated that exosomes (or similar particles) derived from MSCs may suppress OA development. Herein, for first time, we summarize the recent findings of studies on various exosomes derived from MSCs and their effectiveness in the treatment of OA. Moreover, we highlight the likely mechanisms of actions of exosomes in OA.

1 January 2020 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
PNParisa Naeli
Parisa Naeli
MPMohammad Hossein Pourhanifeh
Mohammad Hossein Pourhanifeh
MKMohammad Reza Karimzadeh
Mohammad Reza Karimzadeh
ZSZahra Shabaninejad
Zahra Shabaninejad
AMAhmad Movahedpour
Ahmad Movahedpour
Michael R. HamblinMichael R. Hamblin
Michael R. Hamblin

5 August 2019 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
ZAZahra Alirezaei
Zahra Alirezaei
MPMohammad Hossein Pourhanifeh
Mohammad Hossein Pourhanifeh
SBSarina Borran
Sarina Borran
MNMajid Nejati
Majid Nejati
HMHamed Mirzaei
Hamed Mirzaei
Michael R. HamblinMichael R. Hamblin
Michael R. Hamblin

3 September 2019 in Journal of Ovarian Research
Verified
Journal Article
Open access
PDF file
ZSZahra Shabaninejad
Zahra Shabaninejad
AVAsma Vafadar
Asma Vafadar
AMAhmad Movahedpour
Ahmad Movahedpour
YGYounes Ghasemi
Younes Ghasemi
ANAfshin Namdar
Afshin Namdar
HMHamed Mirzaei
Hamed Mirzaei
Circular RNAs (circRNAs) are a class of long non-coding RNAs (lncRNAs) which have a circular and closed loop structure. They are ubiquitous, stable, conserved and diverse RNA molecules with a range of activities such as translation and splicing regulation, which are able to interacting with RNA-binding proteins and specially miRNA sponge. The expression patterns of the circRNAs exhibited tissue specificity and also, step and stage specificity. Accumulating evidences approved the critical role of circular RNAs in many cancers such as ovarian cancer. Given that these molecules exert their effects through multiple cellular and molecular mechanisms (i.e., angiogenesis, apoptosis, growth, and metastasis) which are involved in cancer pathogenesis, circular RNAs, in particular, act by controlling cell proliferation in ovarian cancer, so that, it has been shown that the deregulation of these molecules is associated with initiation and progression of ovarian cancer. Therefore, they are attractive molecules which have introduced them as cancer biomarkers. Moreover, they could be used as new therapeutic candidates for developing novel treatment strategies. Here, for first time, we have provided a comprehensive review on the recent knowledge of circular RNAs and their pathological roles in the ovarian cancer.

30 December 2020 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
AAAtefeh Amiri
Atefeh Amiri
MPMohammad Hossein Pourhanifeh
Mohammad Hossein Pourhanifeh
HMHamed Mirzaei
Hamed Mirzaei
JNJavid Sadri Nahand
Javid Sadri Nahand
MMMohsen Moghoofei
Mohsen Moghoofei
Michael R. HamblinMichael R. Hamblin
Michael R. Hamblin
: Lung cancer is a malignancy with a high morbidity and mortality rate, and affected patients have low survival and poor prognosis. The therapeutic approaches for the treatment of this cancer, including radiotherapy and chemotherapy, are not particularly effective partly due to late diagnosis. Therefore, the search for new diagnostic and prognostic tools is a critical issue. Novel biomarkers, such as exosomes, could be considered as potential diagnostic tools for malignancies, particularly lung cancer. Exosomes are nanovesicles, which are associated with different physiological and pathological conditions. It has been shown that these particles are released from many cells, such as cancer cells, immune cells and to some degree normal cells. Exosomes could alter the behavior of target cells through intercellular transfer of their cargo (e.g. DNA, mRNA, long non-coding RNAs, microRNAs and proteins). Thus, these vehicles may play pivotal roles in various physiological and pathological conditions. The current insights into lung cancer pathogenesis suggest that exosomes are key players in the pathogenesis of this cancer. Hence, these nanovesicles and their cargos could be used as new diagnostic, prognostic and therapeutic biomarkers in the treatment of lung cancer. Besides the diagnostic roles of exosomes, their use as drug delivery systems and as cancer vaccines is under investigation. The present review summarizes the current information on the diagnostic and pathogenic functions of exosomes in lung cancer.

10 June 2019 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
MPMohammad Hossein Pourhanifeh
Mohammad Hossein Pourhanifeh
RMRezvan Mohammadi
Rezvan Mohammadi
SNSomaye Noruzi
Somaye Noruzi
SHSeyede Atefe Hosseini
Seyede Atefe Hosseini
SFSahar Fanoudi
Sahar Fanoudi
HMHamed Mirzaei
Hamed Mirzaei
Fibromodulin (FMOD) is known as one of very important extracellular matrix small leucine-rich proteoglycans. This small leucine-rich proteoglycan has critical roles in the extracellular matrix organization and necessary for repairing of tissue in many organs. Given that the major task of FMOD is the modulation of collagen fibrillogenesis. However, recently observed that FMOD plays very important roles in the modulation of a variety of pivotal biological processes including angiogenesis, regulation of TGF-β activity, and differentiation of human fibroblasts into pluripotent cells, inflammatory mechanisms, apoptosis and metastatic related phenotypes. Besides these roles, FMOD has been considered as a new tumor-related antigen in some malignancies such as lymphoma, leukemia, and leiomyoma. Taken together, these findings proposed that FMOD could be introduced as diagnostic and therapeutic biomarkers in treatment of various cancers. Herein, for first time, we highlighted the various roles of FMOD in the cancerous conditions. Moreover, we summarized the diagnostic and therapeutic applications of FMOD in cancer therapy.